Last reviewed · How we verify
locally advanced or metastatic urothelial carcinoma uc with disease progression during or following platinum containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum containing chemotherapy in patients who are not eligible for platinum containing chemotherapy and have a pd l1 combined positive score cps 10 as determined by an fda approved test in combination with pembrolizumab and lenvatinib
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- locally advanced or metastatic urothelial carcinoma uc with disease progression during or following platinum containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum containing chemotherapy in patients who are not eligible for platinum containing chemotherapy and have a pd l1 combined positive score cps 10 as determined by an fda approved test in combination with pembrolizumab and lenvatinib patent landscape — cliff calendar, originator estates, attackable patents
- locally advanced or metastatic urothelial carcinoma uc with disease progression during or following platinum containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum containing chemotherapy in patients who are not eligible for platinum containing chemotherapy and have a pd l1 combined positive score cps 10 as determined by an fda approved test in combination with pembrolizumab and lenvatinib treatment landscape brief
- locally advanced or metastatic urothelial carcinoma uc with disease progression during or following platinum containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum containing chemotherapy in patients who are not eligible for platinum containing chemotherapy and have a pd l1 combined positive score cps 10 as determined by an fda approved test in combination with pembrolizumab and lenvatinib treatment updates RSS
Related
- Treatment landscape: locally advanced or metastatic urothelial carcinoma uc with disease progression during or following platinum containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum containing chemotherapy in patients who are not eligible for platinum containing chemotherapy and have a pd l1 combined positive score cps 10 as determined by an fda approved test in combination with pembrolizumab and lenvatinib patent cliff · locally advanced or metastatic urothelial carcinoma uc with disease progression during or following platinum containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum containing chemotherapy in patients who are not eligible for platinum containing chemotherapy and have a pd l1 combined positive score cps 10 as determined by an fda approved test in combination with pembrolizumab and lenvatinib CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing